This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Schizophrenia, unspecified (unspecified schizophrenia)Schizophrenia, unspecified

ICD-10 F20.9 · Special Copayment Reduction V161 (severe intractable disease) · Synonyms: —

Contents

ItemDetails
A. Classification codesICD-10 F20.9 · Special Copayment Reduction V161 (severe intractable disease)
B. Synonyms—
C. Adult onsetSubtype classification not possible (criteria not met or insufficient information); time of onset unclear
1. HistorySchizophrenia classification system and the historical background of the 'unclear' category
2. CausesMultifactorial etiology: genetic, environmental, and neurodevelopmental factors
3. GeneticsGWAS and CNV findings and the genetic heterogeneity of F20.9
4. EpidemiologyPrevalence, incidence, and clinical use of the unspecified code
5. PathophysiologyDopamine, glutamate, and neuroinflammation hypotheses and unclassified schizophrenia
6. SymptomsMixture of positive, negative, and cognitive symptoms and clinical heterogeneity
7. SignsNeurologic and mental status examination and physical signs
8. ScreeningApplication of structured interview instruments and standardized scales
9. DiagnosisICD-10/DSM-5 criteria and conditions for assigning F20.9
10. TreatmentAntipsychotics, psychosocial interventions, and management of treatment uncertainty
11. PrognosisLong-term course, possibility of reclassification, and functional recovery
12. PreventionEarly detection, relapse prevention, and social support system
13. ReferencesGaebel W et al. "Schizophrenia spectrum and other psychotic disorders in ICD-11…" and 9 other papers

1. History

The classification history of schizophrenia (formerly "jeongsinbunyeoljeung") goes back to Emil Kraepelin's concept of dementia praecox in the late 19th century. Kraepelin posited a single disease entity with early onset, chronic course, and cognitive decline at its core, but in clinical practice cases kept appearing whose symptom patterns were too varied to be encompassed in a single category. Eugen Bleuler introduced the term 'Schizophrenie' in 1911 and presented the 4 As (loosening of associations, affective blunting, ambivalence, autism) as core symptoms, but the problem of heterogeneity in clinical phenotype remained unresolved.

The International Classification of Diseases (ICD) system began classifying schizophrenia as an independent disease group with the sixth revision (1948), and as the division into subtypes expanded, an 'unspecified' code became necessary for cases that fit no specific subtype or had insufficient information. ICD-9 used 295.9 for the unspecified type of schizophrenic reaction, and this settled as F20.9 in ICD-10. The DSM system has similarly maintained an 'unspecified' category in Schizophrenia Spectrum and Other Psychotic Disorders.

F20.9 is technically a residual category. That is, it is assigned when the general diagnostic criteria for schizophrenia are met but the case cannot be clearly classified into any specific subtype from F20.0 (paranoid) through F20.8 (other), or when subtype determination is impossible because clinical information is insufficient. In the WHO's ICD-11 revision work, aiming for convergence with DSM-5, most subtype distinctions were abolished and integrated into a single schizophrenia diagnosis, so the role of residual codes such as F20.9 is expected to shrink greatly. However, because ICD-10 is still used as the official classification system in many countries including Korea, the clinical importance of F20.9 continues.

2. Causes

Since schizophrenia, unspecified (F20.9) is a code indicating a state that cannot be classified into a specific subtype, its etiology shares that of the whole schizophrenia spectrum. Schizophrenia is a multifactorial disease rather than one with a single cause, and genetic predisposition, neurodevelopmental abnormalities, prenatal and perinatal environmental factors, and psychosocial stress act in combination.

Genetic factors: Monozygotic twin concordance is about 40–50%, markedly higher than dizygotic (10–15%), suggesting a strong genetic contribution. The sibling risk of onset is about 10 times that of the general population (about 1%). However, the fact that heritability falls short of 100% confirms the independent role of environmental factors. Neurodevelopmental hypothesis: Evidence has accumulated that fetal neuronal migration disorders and abnormal synaptic pruning lead to defects in cortical connectivity. Prenatal infection, nutritional deficiency (folate deficiency), hypoxia, and pregnancy complications raise the risk of onset. Neurotransmitter abnormalities: Mesolimbic dopamine hyperactivity is associated with positive symptoms, and prefrontal dopamine hypoactivity with negative and cognitive symptoms. Glutamatergic NMDA receptor hypofunction (a ketamine-like mechanism) also contributes to explaining the broad range of symptoms. Environmental and social factors: Urban residence, migration experience, minority status, childhood trauma, and cannabis abuse are associated with increased risk of onset.

The group of patients assigned the F20.9 code may, by definition, include absence or incompleteness of clinical information, and thus includes cases in which assessment of causal factors has not been sufficiently done. This further deepens etiologic heterogeneity. Even after assigning an F20.9 diagnosis, the clinician should identify causal factors through further assessment and attempt subtype reclassification.

3. Genetics

The genetic architecture of schizophrenia consists of a combination of hundreds of small-effect common variants and rare high-effect rare variants. A GWAS (genome-wide association study) meta-analysis published in 2022 (Trubetskoy et al., Nature, 2022) identified more than 287 significant loci, highlighting genes related to synaptic function (DRD2, GRIN2A, CACNA1C), histone deacetylation, and immune regulation.

Copy number variants (CNV): The 22q11.2 deletion (associated with DiGeorge syndrome, about 25-fold risk of onset), 15q11.2 deletion, 1q21.1 deletion/duplication, and 16p11.2 deletion have been repeatedly confirmed across the whole schizophrenia spectrum. CNVs are found at a frequency of about 2–3% in sporadic schizophrenia patients, about 5 times higher than in the general population. Rare single nucleotide variants (rare SNV): Loss-of-function variants in synaptic regulatory genes such as SETD1A, TRIO, and RB1CC1 have been reported. These rare variants are distributed across the schizophrenia spectrum as a whole rather than being linked to a specific clinical phenotype.

The genetic characteristics of F20.9 essentially overlap with those of other F20 codes in that there is no genetic signature unique to a specific subtype. Rather, since F20.9 reflects a group with large clinical heterogeneity, genomic studies of these patients can be used to discover new biotypes within the schizophrenia spectrum. The polygenic risk score (PRS) is also significantly high in F20.9 patients, and research on using PRS as a diagnostic aid and for predicting drug response is under way.

4. Epidemiology

The worldwide lifetime prevalence of schizophrenia is about 0.7–1.0%, and the annual incidence is reported at 15–20 per 100,000 population. The actual frequency of use of the unspecified code (F20.9) varies greatly with national diagnostic practices, the quality of clinical records, and the timing of information collection.

Code use: According to multiple national database studies, the proportion of the unspecified code (F20.9) in inpatient statistics is sometimes 10–30% of all schizophrenia diagnoses. This reflects limited information at first admission, limitations of records in emergencies, or the absence of training in systematic subtype classification. Over time, subtype reclassification often takes place during follow-up. Sex differences: In schizophrenia overall, men develop it on average 3–5 years earlier than women (men 18–25 years, women 25–35 years), and a similar sex difference is observed in F20.9. Age: Because age at onset is not clearly defined for F20.9, it may be assigned at various time points, such as the first-episode psychosis (FEP) assessment stage, situations where reclassification is not possible during a chronic course, and late-onset schizophrenia. Korean status: According to Health Insurance Review & Assessment Service (HIRA) data, the number of patients with the schizophrenia (F20) code is about 100,000, with many patients receiving V161 Special Copayment Reduction. Official domestic statistics on the proportion of F20.9 are limited.

5. Pathophysiology

Schizophrenia, unspecified is a clinical category not classified into a specific subtype, but its neurobiological pathophysiology is shared with the entire schizophrenia spectrum. The three most widely accepted core hypotheses at present are the dopamine hypothesis, the glutamate hypothesis, and the neuroinflammation hypothesis.

Dopamine hypothesis: The revised dopamine hypothesis is supported, in which hyperactivity of mesolimbic dopamine D2 receptors mediates positive symptoms (hallucinations, delusions) and decreased D1 receptor function in the prefrontal cortex (PFC) contributes to negative symptoms and cognitive deficits. PET studies consistently report increased striatal dopamine synthesis and release in schizophrenia patients. Glutamate hypothesis (Glutamate/NMDA hypothesis): It began from the observation that NMDA receptor antagonists (ketamine, PCP) induce schizophrenia-like symptoms. The proposed pathway is NMDA receptor hypofunction → disinhibition of inhibitory GABAergic interneurons (especially parvalbumin cells) → glutamate hyperrelease → neurotoxicity. Neuroinflammation hypothesis: Microglial activation, elevated serum cytokines (IL-6, TNF-α, IL-1β), and increased blood-brain barrier permeability are confirmed in many schizophrenia patients. This is especially prominent in the acute phase of symptoms and is associated with decreased prefrontal synaptic density. Neurodevelopmental mechanism: There is a neurodevelopmental model in which abnormal synapse formation around birth and excessive elimination during synaptic pruning in puberty lead to onset. This applies in common to all schizophrenia subtypes including F20.9.

6. Symptoms

F20.9 applies when the diagnostic criteria for schizophrenia are met but the characteristic symptom pattern of a specific subtype is not shown, or symptom information is insufficient. Accordingly, the clinical picture spans the full symptom range of schizophrenia.

Positive symptoms: Auditory hallucinations are the most common and take various forms, such as voices conversing, voices giving commands, and voices commenting on behavior. Delusions may include delusions of reference, persecutory delusions, grandiose delusions, and somatic delusions. Thought disorder may include loosening of associations, thought broadcasting, and thought insertion. Disorganized behavior and speech are also included. Negative symptoms: Flat affect, alogia, avolition, anhedonia, and social withdrawal occur. Cognitive symptoms: Impairments in working memory, attention and concentration, processing speed, and executive function are the main causes of functional impairment. Specific features of F20.9: The background to an F20.9 diagnosis is a situation in which the criteria for classifying a specific subtype (e.g., predominant persecutory delusions in the paranoid type, psychomotor abnormalities in the catatonic type, negative symptoms only in the simple type) are not clearly met, symptoms of several subtypes are mixed, or clinical evaluation has been insufficient.

7. Signs

The signs observed in patients with schizophrenia on psychiatric interview and neurological examination can also appear in F20.9, but the characteristic is that no pattern specific to any single subtype is shown.

Mental status examination (MSE): Poor self-care, inappropriate emotional responses, and distracted or confused behavior may be observed in appearance and behavior. In speech, loosening of associations, flight of ideas, neologisms, and poverty of speech may occur. In affect, flat or inappropriate affect is observed. In perception, hallucinations (auditory most common), depersonalization, and derealization may be reported. In thought content, delusions (persecutory, reference, somatic, etc.) may occur. Reduced insight and impaired judgment are common. Neurological soft signs (NSS): NSS such as reflex abnormalities, dysdiadochokinesis, sensory integration abnormalities, and poor motor coordination are observed in about 50% of patients with schizophrenia. These reflect subtle neurodevelopmental abnormalities. Movement abnormalities: Extrapyramidal symptoms (EPS: parkinsonism, akathisia, acute dystonia) and tardive dyskinesia due to antipsychotics may accompany. Subtle movement abnormalities may be present even before medication. Autonomic signs: Orthostatic hypotension, increased pulse rate, and abnormal sweating related to antipsychotic use may be observed.

8. Screening

Screening for F20.9 uses standard instruments applied across the schizophrenia spectrum, and reclassification into a specific subtype is then sought after sufficient clinical information has been collected.

Structured interview instruments: The Structured Clinical Interview for DSM-5 (SCID-5-CV) and the Mini International Neuropsychiatric Interview (M.I.N.I.) are used for diagnostic confirmation and differential diagnosis. The WHO Schedules for Clinical Assessment in Neuropsychiatry (SCAN) are suitable for ICD-10-based diagnosis. Symptom scales: The Positive and Negative Syndrome Scale (PANSS) consists of 7 positive items, 7 negative items, and 16 general psychopathology items, and quantifies symptom severity and treatment response. The Brief Psychiatric Rating Scale (BPRS) is a rapid 18-item assessment tool useful in emergency and outpatient settings. Cognitive assessment: The MATRICS Consensus Cognitive Battery (MCCB) comprehensively assesses 7 cognitive domains: speed, attention, working memory, verbal memory, visual memory, reasoning, and social cognition. The Montreal Cognitive Assessment (MoCA) can be used for rapid cognitive screening. Functional assessment: The Global Assessment of Functioning (GAF), Personal and Social Performance Scale (PSP), Social and Occupational Functioning Assessment Scale (SOFAS), and others are used. Suicide risk assessment: The Columbia Suicide Severity Rating Scale (C-SSRS) is an essential tool given the high suicide risk in patients with schizophrenia (lifetime suicide attempt rate about 20–40%).

9. Diagnosis

A diagnosis of F20.9 is given when the general ICD-10 criteria for schizophrenia are met but the case clearly fits none of the subtypes F20.0–F20.8. It has the character of a diagnosis of exclusion.

ICD-10 general diagnostic criteria for schizophrenia: For a period of at least 1 month, at least one of the following must be present: ① thought echo, thought insertion, thought withdrawal, thought broadcasting; ② delusions of control, influence, or passivity concerning the body or behavior, or special delusional perception; ③ hallucinatory voices conversing or commenting on behavior; ④ persistent bizarre delusions. Or at least two of the following must be present: ⑤ persistent hallucinations; ⑥ breaks or interpolations in the train of thought; ⑦ catatonic behavior; ⑧ negative symptoms; ⑨ a significant change in the overall quality of the person's behavior. Conditions for assigning F20.9: F20.9 is assigned when the subtype classification criteria are unclear (when symptoms are a mixture of multiple subtypes or fit no subtype), or when clinical information is insufficient or the observation period is inadequate. DSM-5 correspondence: DSM-5 abolished subtypes and adopted a single schizophrenia diagnosis with added specifiers. It corresponds to cases in which even the minimum criteria for 'unspecified schizophrenia spectrum and other psychotic disorder (F29)' are not met. Differential diagnosis: Differentiation from organic psychosis (epilepsy, brain tumor, autoimmune encephalitis, thyroid disease), psychotic episodes of bipolar disorder, schizoaffective disorder, and substance-induced psychotic disorder is essential. Autoimmune encephalitis, including anti-NMDA receptor encephalitis, causes first-episode psychosis resembling schizophrenia and must therefore be excluded.

10. Treatment

Treatment principles for F20.9 follow evidence-based guidelines applied across the whole schizophrenia spectrum. Because the specific subtype is undetermined, initial treatment is approached pragmatically on the basis of the currently prominent symptom profile (predominantly positive symptoms, predominantly negative symptoms, etc.).

Antipsychotics: Second-generation (atypical) antipsychotics are the first-line choice. Risperidone (2–6 mg/day), olanzapine (10–20 mg/day), quetiapine (400–800 mg/day), aripiprazole (10–30 mg/day), ziprasidone, paliperidone, and others are used. Clozapine is the standard treatment for treatment-resistant schizophrenia that does not respond to two or more antipsychotics (agranulocytosis monitoring is mandatory). Long-acting injectables (LAI) are recommended in all schizophrenia subtypes, including F20.9, to improve medication adherence. Psychosocial interventions: Cognitive behavioral therapy (CBT): effective alongside drug treatment for reducing residual symptoms, improving insight, and developing coping strategies. Family intervention: significantly lowers relapse rates by reducing family high expressed emotion (EE). Social skills training (SST), vocational rehabilitation, and supported employment (IPS: Individual Placement and Support) contribute to functional recovery. Evidence is also accumulating for acceptance and commitment therapy (ACT) and mindfulness-based approaches. Physical health management: Patients with schizophrenia are at high risk of metabolic syndrome, diabetes, and cardiovascular disease, so weight, blood pressure, blood glucose, and lipids should be monitored regularly. Management of treatment uncertainty: In F20.9 the subtype is undetermined, so when the symptom pattern becomes clear during follow-up, the diagnosis should be reviewed and the treatment plan refined.

11. Prognosis

The long-term prognosis of schizophrenia has been summarized by the "rule of thirds": about one third show meaningful functional recovery, about one third show partial improvement with repeated relapses, and about one third show a chronic course with persistent functional impairment. However, long-term follow-up studies (the World Health Organization 10-country study, the IEPA early psychosis study) have also presented more optimistic results.

Prognostic features of F20.9: Because F20.9 is often assigned early in diagnosis, there is a possibility of reclassification into a specific subtype during the long-term course. If reclassified as paranoid type (F20.0), a relatively good prognosis can be expected; if reclassified as simple type (F20.6) or residual type (F20.5), the prognosis may be poor. Good prognostic factors: Acute onset, a clear precipitating event, good premorbid social functioning, predominantly positive symptoms, no family history, early treatment initiation, good medication adherence, and strong social support favor prognosis. Poor prognostic factors: Insidious onset, early age at onset, poor premorbid functioning, predominantly negative symptoms, male sex, cognitive decline, family history, comorbid substance abuse, and poor social support worsen prognosis. Suicide risk: About 5–10% of patients with schizophrenia die by suicide, and the lifetime suicide attempt rate reaches 20–40%. The first several years after the first episode are a particularly dangerous period.

12. Prevention

Established interventions for primary prevention of schizophrenia are still limited, but evidence is sufficient for secondary and tertiary prevention through reduction of onset risk and early intervention.

Primary prevention: Strengthened prenatal care (folic acid supplementation, infection prevention, nutritional support), reduction of perinatal complications, prevention of childhood trauma and neglect, and cannabis abuse prevention education may contribute to reducing onset risk. However, owing to the multifactorial causes of schizophrenia, the effect of any single prevention strategy is limited. Intervention in clinical high risk (CHR) states: Early detection and intervention in clinical high-risk states such as attenuated psychosis syndrome (APS), brief limited intermittent psychotic symptoms (BLIPS), and genetic risk and functional deterioration (GRFD) are important. CBT, omega-3 fatty acid supplementation, and low-dose aripiprazole at the CHR stage are being studied for preventing transition to psychosis (Fusar-Poli et al., 2020). Relapse prevention (secondary prevention): Long-term antipsychotic maintenance therapy reduces relapse rates by 50–60%. Use of LAI, family intervention, crisis response planning, and community support systems (ACT: Assertive Community Treatment) are effective for relapse prevention. Training in recognizing early warning signs (sleep disturbance, social withdrawal, increased stress) helps prevent relapse. Tertiary prevention: The goals are intensive case management to prevent long-term hospitalization, vocational rehabilitation and housing support to maintain social functioning, and reduction of excess mortality through physical health management.


References

  1. Gaebel W, Zielasek J, Cleveland HR. "Schizophrenia spectrum and other psychotic disorders in ICD-11: an overview of the changes and their justifications." European Archives of Psychiatry and Clinical Neuroscience. 2022;272(2):173–185. DOI: 10.1007/s00406-021-01248-4
  2. Trubetskoy V, Pardiñas AF, Qi T, et al. "Mapping genomic loci implicates genes and synaptic biology in schizophrenia." Nature. 2022;604(7906):502–508. DOI: 10.1038/s41586-022-04434-5
  3. Leucht S, Leucht C, Huhn M, et al. "Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors." American Journal of Psychiatry. 2017;174(10):927–942. DOI: 10.1176/appi.ajp.2017.16121358
  4. Fusar-Poli P, Cappucciati M, Bonoldi I, et al. "Prognosis of brief psychotic episodes: a meta-analysis." JAMA Psychiatry. 2016;73(3):211–220. DOI: 10.1001/jamapsychiatry.2015.2313
  5. Correll CU, Schooler NR. "Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment." Neuropsychiatric Disease and Treatment. 2020;16:519–534. DOI: 10.2147/NDT.S225643
  6. Howes OD, Kapur S. "The dopamine hypothesis of schizophrenia: version III—the final common pathway." Schizophrenia Bulletin. 2009;35(3):549–562. DOI: 10.1093/schbul/sbp006
  7. Carpenter WT, Bustillo JR, Thaker GK, van Os J, Krueger RF, Green MJ. "The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11." Psychological Medicine. 2009;39(12):2025–2042. DOI: 10.1017/S0033291709990286
  8. Lally J, MacCabe JH. "Antipsychotic medication in schizophrenia: a review." British Medical Bulletin. 2015;114(1):169–179. DOI: 10.1093/bmb/ldv017
  9. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. "Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review." Archives of General Psychiatry. 2005;62(9):975–983. DOI: 10.1001/archpsyc.62.9.975
  10. Vos T, Barber RM, Bell B, et al. (Global Burden of Disease Study 2013 Collaborators). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013." The Lancet. 2015;386(9995):743–800. DOI: 10.1016/S0140-6736(15)60692-4